Unknown

Dataset Information

0

Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs.


ABSTRACT: Multicellular spheroids comprised of malignant cells, endothelial cells, and mesenchymal stem cells served as an in vitro model of human solid tumors to investigate the potentiation of DNA-damaging drugs by pharmacologic modulation of DNA repair pathways. The DNA-damaging drugs, topotecan, trabectedin, and temozolomide were combined with varied inhibitors of DNA damage response enzymes including PARP (olaparib or talazoparib), ATM (ataxia telangiectasia mutated; AZD-1390), ATR (ataxia telangiectasia and Rad3-related protein; berzosertib or elimusertib), and DNA-PK (DNA-dependent protein kinase; nedisertib or VX-984). A range of clinically achievable concentrations were tested up to the clinical Cmax, if known. Mechanistically, the types of DNA damage induced by temozolomide, topotecan, and trabectedin are distinct, which was apparent from the response of spheroids to combinations with various DNA repair inhibitors. Although most combinations resulted in additive cytotoxicity, synergistic activity was observed for temozolomide combined with PARP inhibitors as well as combinations of the ATM inhibitor AZD-1390 with either topotecan or trabectedin. These findings might provide guidance for the selection of anticancer agent combinations worthy of further investigation.

Significance

Clinical efficacy of DNA-damaging anticancer drugs can be influenced by the DNA damage response in tumor cells. The potentiation of DNA-damaging drugs by pharmacologic modulation of DNA repair pathways was assessed in multicellular tumor spheroids. Although most combinations demonstrated additive cytotoxicity, synergistic cytotoxicity was observed for several drug combinations.

SUBMITTER: Dexheimer TS 

PROVIDER: S-EPMC10452929 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs.

Dexheimer Thomas S TS   Coussens Nathan P NP   Silvers Thomas T   Wright John J   Morris Joel J   Doroshow James H JH   Teicher Beverly A BA  

Cancer research communications 20230825 8


Multicellular spheroids comprised of malignant cells, endothelial cells, and mesenchymal stem cells served as an <i>in vitro</i> model of human solid tumors to investigate the potentiation of DNA-damaging drugs by pharmacologic modulation of DNA repair pathways. The DNA-damaging drugs, topotecan, trabectedin, and temozolomide were combined with varied inhibitors of DNA damage response enzymes including PARP (olaparib or talazoparib), ATM (ataxia telangiectasia mutated; AZD-1390), ATR (ataxia tel  ...[more]

Similar Datasets

| S-EPMC8003921 | biostudies-literature
| S-EPMC3598667 | biostudies-literature
| S-EPMC6950217 | biostudies-literature
| S-EPMC5059692 | biostudies-literature
| S-EPMC3280152 | biostudies-literature
| S-EPMC5843470 | biostudies-literature
| S-EPMC3560920 | biostudies-literature
| S-EPMC9179573 | biostudies-literature
| S-EPMC3941083 | biostudies-literature
| S-EPMC6129576 | biostudies-literature